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Purpose: We examined the relationship between high myopia and common polymorphisms in four candidate genes:
collagen, type XI, alpha 1 (COL11A1); collagen, type XVIII, alpha 1 (COL18A1); fibrillin 1 (FBN1); and procollagen-
lysine 1,2-oxoglutarate 5-dioxygenase 1 (PLOD1). These genes were selected because rare pathogenic mutations in these
genes cause disease syndromes that have myopia, usually high myopia, as one of the common presenting features.
Methods: This study recruited 600 unrelated Han Chinese subjects including 300 cases with high myopia (spherical
equivalent or SE≤-8.00 diopters) and 300 controls (SE within ±1.00 diopter). A total of 66 tag single nucleotide
polymorphisms (SNPs) were selected for study from these four candidate genes. The study adopted a DNA pooling strategy
with an initial screen of DNA pools to identify putatively positive SNPs and then confirmed the “positive” SNPs by
genotyping individual samples forming the original DNA pools. DNA pools were each constructed by mixing equal
amounts of DNA from 50 individuals with the same phenotype status. Six case pools were prepared from 300 cases and
six control pools from 300 controls. Allele frequencies of DNA pools were estimated by analyzing the primer-extended
products with denaturing high performance liquid chromatography and compared between case pools and control pools
with nested ANOVA.
Results: In the first stage, 60 SNPs from the 4 candidate genes were successfully screened using the DNA pooling
approach. Of these, 6 SNPs showed a statistical significant difference in estimated allele frequencies between case pools
and controls at p<0.10. In the second stage, these “positive” SNPs were followed up by individual genotyping, but failed
to be confirmed via standard single-marker and haplotype analyses.
Conclusions: Common polymorphisms in these four candidate genes (COL11A1, COL18A1, FBN1 and PLOD1) were
unlikely to play important roles in the genetic susceptibility to high myopia.
Myopia is the commonest ocular disorder in the world.
In general, it is more prevalent in Oriental populations (60%–
80%) than in Caucasian populations (10%–25%) [1]. Subjects
with high myopia, usually defined as −6.0 diopters (D) or
worse, are more vulnerable to ocular pathologies later in their
life, such as cataract, glaucoma and retinal detachment [2].
Myopia is a complex disease with contribution from genetic
factors, environmental factors and their interactions [3,4].
Genetic association studies are usually used to identify
myopia susceptibility genes, which tend to have small effect
size [4,5]. Genome-wide association studies generate
hypotheses for subsequent follow-up and are the method of
choice, but are still beyond the reach of many research groups
in terms of the cost. Another popular approach is to examine
candidate genes, which are usually selected on the basis of
their biology and function [4,6]. Genes underlying heritable
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disease syndromes with myopia as one of the common
presenting features can be selected as myopia candidate genes
for study [4,6].
Stickler syndrome is an autosomal dominant disease
affecting types II and XI collagen expressed in vitreous and
cartilage, and has highly variable clinical features affecting
the eye, the ear and joints [7,8]. In particular, Stickler
syndrome types 1 and 2 (STL1 and STL2) have myopia and
abnormal vitreous while type 3 is a non-ocular form of the
syndrome. STL1 is caused by mutations in the collagen, type
II, alpha 1 (COL2A1) gene while STL2 arises from mutations
in the collagen, type XI, alpha 1 (COL11A1) gene.
Interestingly, COL11A1 mutations are also known to cause
Marshall syndrome or Marshall/Stickler syndrome, which
both have myopia as a common feature [7,8]. Knobloch
syndrome is an autosomal recessive disease characterized by
high myopia, vitreoretinal degeneration and occipital
encephalocele, and is caused by mutations in the collagen,
type XVIII, alpha 1 (COL18A1) locus [8-10]. Marfan
syndrome is an autosomal dominant disorder of connective
tissue with major manifestations affecting the ocular, skeletal
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and cardiovascular systems [11,12]. The major ocular
abnormalities are lens dislocation and high myopia due to
increased axial length. Marfan syndrome is classically caused
by mutations in the fibrillin 1 (FBN1) gene. Ehlers-Danlos
syndrome is a heterogeneous group of genetic disorders with
major clinical features of skin hyper-extensibility, atrophic
scarring, join hyper-mobility and generalized tissue fragility
[11]. Type VI or the kyphoscoliotic form of Ehlers-Danlos
syndrome is autosomal recessive in nature with added clinical
features of kyphoscoliosis (a form of curved spine) and scleral
fragility [11,12]. High myopia is also a common feature [13].
The kyphoscoliotic form of Ehlers-Danlos syndrome is
caused by mutations in the PLOD1 gene, which encodes the
enzyme procollagen-lysine 1,2-oxoglutarate 5 dioxygenase-1
(PLOD1; also known as lysyl hydroxylase 1) responsible for
forming cross-links in collagens via hydroxylysine-based
pyridinoline.
The genes responsible for these syndromes are expressed
in various parts of the eye. These disease syndromes are
caused by rare pathogenic loss-of-function mutations that are
not found in healthy individuals. The mechanisms leading to
the common occurrence of myopia, usually high myopia, in
these syndromes are not well established. We hypothesized
that common polymorphisms in these genes could be
predisposing genetic factors for high myopia [4,6]. Indeed,
common polymorphisms in COL2A1 – the causative gene for
STL1 – have been found to be associated with myopia in two
family-based association studies [14,15]. In this study, we
evaluated COL11A1, COL18A1, FBN1, and PLOD1 (Table 1)
as candidate genes for high myopia in a Chinese population
with a case-control study approach.
We performed the study with an initial screen of DNA
pools to identify putatively positive single nucleotide
polymorphisms (SNPs) and then confirmed the “positive”
SNPs by genotyping individual samples forming the original
DNA pools. The initial screen of DNA pools was to cut down
the time and cost involved in sample-by-sample genotyping
[4,16]. DNA pools were constructed by mixing equal amounts
of DNA from many subjects with the same disease status. In
the present study, “case pools” were prepared from
individuals with high myopia (cases) and “control pools” from
emmetropes (controls). Allele frequencies of DNA pools were
estimated by analyzing the primer-extended products with
denaturing high performance liquid chromatography
(DHPLC) [17] and compared between case pools and control
pools with a proper statistical method, nested ANOVA
(ANOVA) [18].
METHODS
Subjects: This study recruited 600 unrelated Han Chinese
individuals including 300 cases with high myopia (spherical
equivalent or SE ≤-8.00 D for both eyes) and 300 control
subjects (SE within ±1.00 D for both eyes). The study was
approved by the Human Subjects Ethics Subcommittee of the
Hong Kong Polytechnic University and adhered to the tenets
of the Declaration of Helsinki. Written informed consents
were obtained from all participating subjects. Eye
examination for all participants was conducted in the
Optometry Clinic of the University, blood samples were
collected and DNA was extracted as has been described
previously [19]. Of particular relevance to this study was the
exclusion of subjects who showed obvious signs of ocular
disease or other inherited disease associated with myopia
(e.g., Stickler syndrome, Marshall syndrome, Knobloch
syndrome, Marfan syndrome, Ehlers Danlos syndrome, etc).
Construction of DNA pools: A PicoGreen method (Invitrogen,
Carlsbad, CA) was used to quantify accurately all DNA
samples in accordance with the manufacturer’s protocols. The
DNA samples were then diluted to 5.0±0.3 ng/μl, and then
mixed in equal volumes to construct DNA pools. DNA from
50 distinct individuals sharing the same phenotype was mixed
to construct a single pool. In total, six case pools were
constructed from 300 cases, and six control pools from 300
controls.
Tag SNP selection: Four candidate genes were investigated in
this study: COL11A1, COL18A1, FBN1, and PLOD1 (Table
1). With the Tagger program [20], the following criteria were
used to select tag SNPs from each of the gene of interest and
its adjoining genomic region (3 kb upstream and 3 kb
downstream): pairwise tagging algorithm, r2≥0.8 and minor
allele frequency (MAF) ≥0.10. The Han Chinese genotype
data from the International HapMap Project database (release
23a, phase II) were used for tag SNP selection. In total, 66 tag
SNPs were selected from these four candidate genes and
screened by the DNA pooling strategy (Table 1).
Estimation of allele frequencies in DNA pools: Genomic DNA
(individual or pooled) was amplified for each SNP with a
touchdown protocol in a 15-μl reaction mixture, which
contained 0.1 or 0.3 μM of each primer, 1.5 or 2.5 mM
TABLE 1. SUMMARY OF TAG SNPS IN THE COL11A1, COL18A1, FBN1, AND PLOD1 GENES.
Gene GeneID No. of exons Chromosmal
location
Region
captured
No. of tSNPs
selected
No. of SNPs captured
at mean r2=?
COL11A1 1301 68 1p21 238 kb 8 85 (r2=0.969)
COL18A1 80781 43 21q22.3 115 kb 30 81 (r2=0.956)
FBN1 2200 66 15q21.1 243 kb 19 142 (r2=0.925)
PLOD1 5351 19 1p36.22 47 kb 9 16 (r2=0.980)
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MgCl2 (Table 2), 0.2 mM of each dNTP, 25 ng of DNA and
0.2 unit of DNA polymerase (HotStarTaq Plus; Qiagen,
Hilden, Germany) in 1× PCR buffer supplied by the
manufacturer. All primers were designed using the OLIGO
software (version 6.57; Molecular Biology Insights, Cascade,
CO). A thermal cycler (GeneAmp PCR System 9700; Applied
Biosystems, Foster City, CA) was used for the touchdown
PCR: (1) initial denaturation of 5 min/95 °C; (2) 6 touchdown
cycles of 30 s/95 °C, 45 s/62 °C or 64 °C (initial annealing
temperature, Table 2) with a decrease of 1 °C per cycle, and
45 s/72 °C; (3) additional 38 cycles of 30 s/95 °C, 45 s/56 °C
or 58 °C (final target annealing temperature, Table 2), and 45
s/72 °C; and (4) final extension of 7 min/72 °C. PCR products
were then purified using exonuclease I (New England Biolabs,
Beverly, MA) and shrimp alkaline phosphatase (GE
Healthcare, Piscataway, NJ).
Primer extension (PE) reaction was performed in a 25-
μl reaction mixture, which contained 10 μl of purified PCR
product, 1.5 μM of a specific PE primer (Table 2), 50 μM of
each appropriate ddNTP (Table 2) and 1 unit of Therminator
(New England Biolabs, Beverly, MA) in a 1× reaction buffer
provided by the manufacturer. Amplification was conducted
as follows: initial denaturation of 1 min/96 °C, followed by
55 cycles of 10 s/96 °C, 15 s/43 °C and 1 min/60 °C. The
WAVE Nucleic Acid Fragment Analysis System
(Transgenomic, Omaha, NE) was used for DHPLC analysis
of primer extended products. PE products were analyzed as
described previously [21] with the following modifications: a
6% linear gradient change of the working elution buffer over
a 3-min period and a different starting concentration of buffer
B, which varied with the SNP being studied (Table 2).
Estimation of the relative allele frequencies in DNA pools
was based on the peak heights of the PE products as analyzed
by DHPLC. Each DNA pool was analyzed in three replicates,
and each replicate consisted of a single PCR followed by a
single PE reaction and a single DHPLC analysis. Therefore,
each SNP had 36 sets of readings for 6 case pools and 6 control
pools. For each SNP, a heterozygous sample was first
identified by screening 10 to 40 subjects, and then analyzed
in three independent runs to obtain a mean value for the so-
called “k correction factor” that was used to correct for
differential incorporation of ddNTPs in PE reactions as
described previously [17].
Individual genotyping: The positive findings (6 SNPs) in the
initial screen of DNA pools were confirmed by genotyping
the individual samples that formed the original DNA pools.
The MassARRAY iPLEX Gold assay was used to genotype
the samples in accordance to the manufacturer’s protocols for
5 SNPs (Table 3). Because of the multiplexing format of the
MassARRAY system, these SNPs were grouped and
genotyped together with SNPs of other studies by a local
service provider. One SNP (rs2838922) could not be grouped
TABLE 3. PRIMERS FOR GENOTYPING INDIVIDUAL SAMPLES.
Gene, SNP Primer sequences (5′>3′)*
MassArray iPLEX Gold assay (Sequenom)
COL11A1, rs17127311 F: ACGTTGGATGCCTTTAGACTTCACATTCTC
 R: ACGTTGGATGGTATTAAGGAAAAAGCAAAGC
 PE primer: cccacGGAAAAAGCAAAGCAAAGTGATG
COL18A1, rs11911327 F: ACGTTGGATGTTTGCGTGGCTGCCTGGCCT
 R: ACGTTGGATGGACTCACAGATGCCTTTTGC
 PE primer: caTTCCCACAGCGCTGC
COL18A1, rs2236454 F: ACGTTGGATGCAGAAGCCAAGGACAGAAAC
 R: ACGTTGGATGATTGGGTCCGGACGGAATG
 PE primer: aaagcGATCCAGGAAACTCCCC
COL18A1, rs2236457 F: ACGTTGGATGGCTACAGGAGAGCACAGAAA
 R: ACGTTGGATGTCTATGACAGGAAAAGTCCC
 PE primer: aacaCCAAAATATACCACTTGGGG
COL18A1, rs2236475 F: ACGTTGGATGGCCAGTACCCAGGAGGAAG
 R: ACGTTGGATGTGACTGAGCCTAGCACACAC
 PE primer: ggacGGCCCACTGCCCTGTCTGCC
Restriction fragment length polymorphism
COL18A1, rs2838922 F: CTGCTTCCCCACCTTTTCAC
 R: (T)20 CTGAGATGTGAGAATCGCTCGA
        *F=forward primer; R=reverse primer; and PE=primer extension. Note that bases in lower case are added to the PE primers to
        allow better size discrimination of the primer extended products in the multiplex assays of the MassARRAY system.
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together with other SNPs for the MassARRAY system, and
was genotyped by the method of restriction fragment length
polymorphism (Table 3). The fragment was amplified using
touchdown PCR as described above with the following
specific conditions: 0.1 μM of each primer, 1.5 mM MgCl2,
64 °C as the initial annealing temperature and 58 °C as the
final target annealing temperature. Overnight digestion of the
PCR products by TaqI (Fermentas, Vilnius, Lithuania) at
65 °C was performed according to the manufacturer’s
instructions. Digested products were separated by
electrophoresis in polyacrylamide gels.
Statistical analysis: Ocular data were analyzed with the
STATA package (version 8.2; StataCorp, College Station,
TX). Subjects were classified as cases (affected with high
myopia) or controls (unaffected). For a given SNP, the relative
allele frequencies were estimated from the peak heights of the
two extension products and adjusted using the k correction
factor according to the method reported by Hoogendoorn et
al. [17]. With the STATA package, nested ANOVA [18] was
used to compare the relative allele frequencies of the case
pools and the control pools. A p value ≤0.10 for the
comparison between case pools and control pools was used as
the threshold for following up SNPs with individual
genotyping. Genotype data of individual samples were tested
for Hardy–Weinberg equilibrium (HWE), and compared
between cases and controls for association. The PLINK
package (version 1.07) [22] was used for analysis. The linkage
disequilibrium measures were calculated and plotted using
Haploview (version 4.2) [23]. Haplotype blocks were
constructed using the algorithm known as the solid spine of
LD, which is unique to Haploview. Potential interactions
among SNPs were examined using the method of multifactor
dimensionality reduction (MDR) [24].
RESULTS
Analysis of the ocular data: The characteristics of the
participating subjects have been reported in one of our
previous studies [19]. They are briefly summarized as follows.
The average SE was −10.53 (range: −24.00 to −8.00) D for
cases, and 0.03 (range: −1.00 to 0.88) D for controls. The
average axial length was 27.76 (range: 24.62 – 31.29) mm for
cases, and 23.85 (range: 21.24 to 27.71) mm for controls.
These ocular data are for the right eyes. The average age was
27.7 (range: 15 to 48) years for cases, and 24.9 (range: 17 to
46) years for controls. There were more male subjects in the
control group than in the case group (43.7% vs 28.3%,
p=4.30×10−5).
Analysis of results for DNA pools: The results are summarized
in Table 4. Of the 66 tag SNPs selected for study, 6 did not
give any results because of failure in PCR or PE even after
repeated optimization as noted in a footnote of Table 2. For
the 60 SNPs successfully analyzed, the k correction factor
ranged from 0.29 to 1.56 with a mean of 1.02; it ranged from
0.83 to 1.21 for 54 SNPs (90% of the SNPs analyzed). The
estimated frequencies of the first eluted alleles ranged from
0.1041 to 0.9246 for case pools, and from 0.0929 to 0.9516
for control pools. The difference (case pools – control pools)
in estimated allele frequencies varied from −0.0510 to 0.0337.
At a lenient threshold of p≤0.10, six SNPs gave significant
results, which were followed up with individual genotyping
for confirmation. These included one SNP in the COL11A1
gene: rs17127311 (difference=-0.0325, p=0.0981). The other
five “positive” SNPs were in the COL18A1 gene: rs2838922
(difference=0.0367, p=0.0572), rs11911327
(difference=-0.0315, p=0.0959), rs2236454
(difference=-0.0510, p=0.0629), rs2236457
(difference=0.0255, p=0.0779), and rs2236475
(difference=-0.0367, p=0.0852). No significant difference in
allele frequencies was demonstrated in the remaining 55
SNPs, which were thus not tested any further.
Confirmation of pooled DNA results by individual
genotyping: The genotypes of these six SNPs were in HWE
except two SNPs (rs2838922 and rs223475) in cases and two
SNPs (rs17127311 and rs2838922) in controls (Table 5).
Deviation from HWE in cases can be a signal for SNP-disease
association [25]. The two SNPs violating HWE in controls
(rs17127311 and rs2838922) were dropped from subsequent
analysis. One haplotype block was constructed for three SNPs
as shown in Figure 1. All four SNPs were analyzed for
association with high myopia with adjustment for gender, but
did not show significant differences in allele frequencies
between cases and controls (Table 5). Sliding window-based
haplotype analysis of these four SNPs (rs11911327 [S1],
rs2236454 [S2], rs2236457 [S3], and rs2236475 [S4] in the
5′>3′ order along the sense strand of the COL18A1 gene) did
not show any association with high myopia either. The p
values for the omnibus tests of haplotypes adjusted for gender
were as follows: 0.2000 (S1-S2), 0.2850 (S2-S3), 0.1860 (S3-
S4), 0.2560 (S1-S2-S3), 0.1840 (S2-S3-S4), and 0.2810 (S1-
S2-S3-S4). MDR did not show any significant interaction
among the SNPs either, with the best model consisting of all
four SNPs (p=0.1719).
DISCUSSION
This study explored the relationship of common
polymorphisms in four candidate genes (COL11A1,
COL18A1, FBN1, and PLOD1) with high myopia in a Han
Chinese population. Rare pathogenic mutations in these
candidate genes cause disease syndromes that have myopia,
usually high myopia, as one of the common presenting
features [8-13]. It was logical to investigate whether common
polymorphisms of these genes would be predisposing genetic
factors for high myopia. This argument was strengthened by
the positive association between common polymorphisms of
the COL2A1 gene, the causative gene underlying STL1, and
myopia [14,15]. The relationship between the selected
candidate genes and high myopia has not been studied before.
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With this background, we examined these candidate gene
with an efficient approach based on the initial screening of
DNA pools. Six case pools and six control pools were
constructed and screened by DHPLC analysis of primer
extended products. Our case subjects were recruited with a
refractive error (SE) threshold of at least −8.00 D for both
eyes, and the average SE was −10.53 D. Such a high threshold
was adopted for case subject recruitment so as to enrich the
contribution of genetic factors to the extreme phenotype and
to enhance the homogeneity of the case phenotype [4,6]. Our
control subjects were emmetropic and were not randomly
recruited from the general Chinese population in Hong Kong.
This would also enhance the difference in the genetic
components contributing to the phenotype difference between
our cases and controls. Random population-based controls
were less desirable because they would be enriched with
subjects with mild  to moderate myopia from our population
– a population with a high prevalence of myopia [26]. These
strategies would enhance the power of our study.
In the first stage, 60 SNPs from the 4 candidate genes
were successfully screened using the DNA pooling approach.
Of these, 6 SNPs gave a p value of less than 0.10 for the
statistical comparison of allele frequency differences between
case pools and control pools by nested ANOVA (Table 4). A
TABLE 5. ALLELIC ASSOCIATION TESTS OF COL11A1 AND COL18A1 SNPS GENOTYPED INDIVIDUALLY.
 Alleles* Genotype counts (11/12/22)* HWE test (p value) Minor allele freq Allelic test†
SNP 1 2 Cases Controls Cases Controls Cases Controls OR (95% CI) p value
COL11A1
rs17127311 A G 206/74/5 165/89/2 0.8128 0.0054 0.1474 0.1816 – ‡ – ‡
COL18A1
rs2838922 C T 197/75/26 174/91/28 4.47E-05 0.0047 0.2131 0.2509 – ‡ – ‡
rs11911327 C T 197/89/10 192/97/7 1.0000 0.2524 0.1841 0.1875 0.98 (0.72 - 1.33) 0.8979
rs2236454 C T 74/131/90 79/144/73 0.0621 0.6431 0.5271 0.4899 1.15 (0.92 - 1.44) 0.2132
rs2236457 C T 183/94/22 180/93/14 0.0508 0.7221 0.2308 0.2108 1.10 (0.84 - 1.44) 0.5011
rs2236475 A G 184/88/22 176/96/21 0.0187 0.1427 0.2245 0.2355 0.93 (0.71 - 1.20) 0.5672
        *The major allele is designated as “1” and minor allele as “2”; and the genotype counts are indicated as the counts of the
        genotypes 11, 12, and 22, respectively. This study had 300 cases and 300 controls. Note that the total genotype counts may not
        add up to these expected numbers because a few samples failed to be genotyped in a random fashion. †The allelic test is performed
        with the gender as a covariate to adjust for the potential confounding by gender because the cases and controls differ significantly
        in the proportions of male and female subjects (p=4.30×10–5).The odds ratio (OR) is calculated for the minor allele (allele 2)
        with the major allele (allele 1) as the reference. ‡ Association tests are not performed for these two SNPs (rs17127311 and
        rs2838922) because the genotypes in the controls are not in Hardy–Weinberg equilibrium (HWE).
Figure 1. Single nucleotide
polymorphisms (SNPs) and their
linkage disequilibrium (LD) for the
COL18A1 gene. The SNPs are indicated
from the 5′ end (left) to the 3′ end (right)
of the gene. The LD measures are
expressed as D’ and r2 for all subjects
under study (cases and controls
combined), and are calculated by
Haploview. The shades of red (for D’)
and gray (for r2) represent the magnitude
of the measures with deep red equal to
100% (or 1.00), which is omitted in the
diagram to avoid cluttering.
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lenient significance threshold of p≤0.10 was used to avoid
missing potentially significant SNPs. In the second stage,
these “positive” SNPs were followed up by individual
genotyping, but failed to be confirmed via standard single-
marker (Table 5) and haplotype analyses. In conclusion,
common polymorphisms in these four candidate genes
(COL11A1, COL18A1, FBN1, and PLOD1) were unlikely to
play important roles in the genetic susceptibility to high
myopia.
It is interesting to note that deviations from HWE were
observed in the control group for two SNPs (rs17127311 and
rs2838922; Table 5). The Hardy–Weinberg principle assumes
a very large population in which mating is random and there
are no migration, mutation and natural selection [27].
Theoretically, violations of these assumptions can result in
deviations from HWE. However, deviations from HWE can
indicate the presence of genotyping errors [28]. We had been
very careful in carrying out the genotyping and calling the
genotypes, and we confirmed any ambiguous genotypes by
direct DNA sequencing. However, we cannot entirely rule out
the possibility of genotyping errors as a cause for deviations
from HWE. It is generally recommended not to perform case-
control comparison for such genotype data to avoid false
positive association results [28].
We used nested ANOVA [18] to test for differences in
estimated allele frequencies between case pools and control
pools. Nested ANOVA can properly handle the variance
components of the errors arising from sampling of the subjects
in forming the pools and of the technical errors arising from
various stages of allele frequency estimation, e.g., unequal
amounts of individual DNA samples in forming the pools,
errors in PCR and primer extension reaction, and in DHPLC
analysis. However, the individual variance components could
not be estimated directly. Thus, it was not possible to calculate
the power of our DNA pooling based-approach, which would
expectedly be less than the power of an approach based on
genotyping of all individual samples for all tag SNPs. In
addition, our DNA pooling strategy did not allow haplotype
analysis for SNPs only examined for the DNA pools [16]. On
the other hand, we enhanced the power of our study by using
stringent criteria for recruiting the cases (extreme phenotype)
and the controls (supernormal), as has been discussed above
[4,6,26].
DNA pooling has been proven to be effective as an initial
screen of SNPs to search for putative genetic markers
associated with a phenotype of interest for subsequent follow-
up studies based on conventional genotyping of individual
samples [16,29]. Saving in the amounts of DNA used and in
the cost and time involved in genotyping is the major
advantage of DNA pooling. For each SNP, 36 separate PCRs
and the following analyses were needed for 6 case pools and
6 control pools together with 3 other separate PCRs for a
heterozygous sample to determine the k correction factor. In
comparison to genotyping 600 samples individually, our
current DNA pooling approach could theoretically reduce the
amounts of DNA used and the genotyping work by up to
93.5%. Note that we mixed DNA from 50 distinct individuals
to form one DNA pool. This approach of using more pools of
smaller size has been shown to be superior to the use of fewer
DNA pools each formed from a larger number of subjects for
genetic association studies of candidate genes [30].
It may seem that DNA pooling may become less
attractive with the recent tremendous reduction in the unit cost
of genotyping for high-throughput array-based whole-
genome genotyping assays. However, the total cost of such
genome-wide genotyping is still too expensive and hence
unaffordable for most research groups. Use of DNA pools for
genome-wide genotyping is one of the solutions proposed
[31]. Recent studies even suggest the use of DNA pools for
deep sequencing using next-generation sequencing
technologies to explore the role of rare variants in complex
diseases [32,33] because both common and rare variants are
believed to contribute to the genetic susceptibility to complex
diseases [34]. This new development is particularly important
because deep sequencing is even more expensive and
produces even larger amounts of data for analysis than
genome-wide genotyping. Note that the present study did not
address the potential role of rare variants that may contribute
to the genetic susceptibility to high myopia, but do not cause
the respective Mendelian disease syndromes mentioned
above. Indeed, there are already rare variants reported to be
associated with high myopia but not congenital stationary
night blindness ([35] and unpublished data). Congenital
stationary night blindness is an X-linked monogenic ocular
disease with high myopia as one of its common presenting
features [36].
In summary, we examined using a DNA pooling
approach tag SNPs from four candidate genes (COL11A1,
COL18A1, FBN1, and PLOD1) selected because pathogenic
mutations in these genes cause disease syndromes that have
myopia, usually high myopia, as one of the common
presenting clinical features. Six SNPs were followed up by
individual genotyping, but did not demonstrate any
association with high myopia. We concluded that common
polymorphisms in these candidate genes were unlikely to be
important in the genetic susceptibility to high myopia in Han
Chinese.
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